Article: Intellectual Property Due Diligence in Psychedelics
Cannabis Law Report
JUNE 19, 2022
Given that the compounds are Schedule I substances, there is also a keen interest in innovative packaging and drug delivery devices. Originally Published At Microdose. As we see more data emerge from clinical trials, we are likely to see patent applications covering stability, pharmacokinetic, and pharmacodynamic data.
Let's personalize your content